T he rate of stroke in nonvalvular atrial fibrillation (AF) ranges widely and depends on the presence of prior cerebral ischemia, comorbid conditions, and use of antithrombotic therapy. Without antithrombotic therapy, the rate varies from fewer than 2 to more than 10 strokes per 100 patient-years. [1] [2] [3] [4] [5] [6] [7] Although adjusted-dose warfarin is superior to aspirin for reducing stroke in AF patients, the absolute risk reduction is determined by the stroke risk with aspirin therapy. 8, 9 Thus, quantifying the risk of stroke is crucial for determining which AF patients would benefit most from warfarin therapy. Patients whose risk is less than Ϸ2 strokes per 100 patient-years with aspirin have little to gain from warfarin therapy; for these patients, the risks of warfarin tend to outweigh any benefits. 9 -11 A risk stratification scheme that reliably identified these low-risk patients could spare them the risks, inconvenience, and costs associated with anticoagulation. In contrast, for AF patients whose risk exceeds 4 strokes per 100 patient-years of aspirin therapy, warfarin therapy consistently improves quality-adjusted survival. 4, 10, 12 Between these 2 extremes are patients for whom the key issue is whether stroke risk can be quantified reliably so that antithrombotic therapy can be judiciously selected on the basis of stroke risk, hemorrhage risk, and individual preferences. 10, 13, 14 Risk stratification schemes that accurately and reliably stratify stroke risk could influence the antithrombotic management of millions of people who have AF. Because patients with a prior stroke or transient ischemic attack (TIA) are at high risk of stroke, the greatest need is to quantify stroke risk in the AF primary prevention population. Here, we use prospective data to test the predictive accuracy of 5 widely available stroke risk stratification schemes and provide reliable guidance to clinicians selecting antithrombotic therapy.
Methods

Risk Stratification Schemes
Multivariate analyses of prospective cohorts of AF patients who were prescribed aspirin or no antithrombotic therapy yielded independent predictors of stroke that formed the basis of 5 previously published risk stratification schemes (Appendix). 2, 4, 15, 16 In 1994, the Atrial Fibrillation Investigators (AFI) conducted a multivariate analysis of pooled data from 1593 untreated AF participants in 5 randomized clinical trials. 4 Participants with prior cerebral ischemia (either stroke or TIA), hypertension, or diabetes mellitus were at high risk of stroke; patients without these risk factors were at moderate risk of stroke if older than 65 years and at low risk otherwise (Table 1) .
The Stroke Prevention and Atrial Fibrillation (SPAF) investigators developed a classification scheme from 854 SPAF I and II participants treated with aspirin. 15 Four factors independently predicted a high risk of stroke: prior cerebral ischemia, the combination of age greater than 75 years plus female gender, left ventricular dysfunction (defined as recent clinical heart failure or left ventricular fractional shortening Յ25% by echocardiography), and systolic blood pressure Ͼ160 mm Hg (Table 1) . SPAF participants with a history of hypertension but blood pressure Յ160 mm Hg were found to have a moderate risk (Ϸ3 strokes per 100 patient-years), 5, 15 and participants with none of these factors were at low risk of stroke (Table 1) .
In 1998 and 2001, the American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy classified patients as high risk if they had prior cerebral ischemia (or systemic embolism), hypertension, congestive heart failure (either clinical heart failure or poor systolic function on echocardiography), age Ͼ75 years, or at least 2 moderate-risk factors. 16, 17 The moderaterisk factors were age 65 to 75 years, diabetes mellitus, and coronary artery disease. Patients with 1 moderate-risk factor were classified as moderate risk, and patients with none of the risk factors were classified as low risk.
In 2001, an amalgamation of the AFI and SPAF schemes led to the CHADS 2 scheme. 2 The CHADS 2 acronym was derived from the individual stroke risk factors: Congestive heart failure, Hypertension, Age Ͼ75 years, Diabetes mellitus, and prior Stroke or TIA. Two points were given for prior stroke or TIA (hence, the subscripted "2"), and 1 point was assigned for each of the other factors. The point system was designed to simplify the determination of stroke risk in general practice. CHADS 2 stroke rates ( 18 developed a risk classification scheme based on 868 Framingham participants, some of whom were taking warfarin or aspirin therapy. Using the coefficients from a Cox proportional survival model, they developed a point system based on age (0 to 10 points), gender (6 points for female; 0 for male), blood pressure (0 to 4 points), diabetes mellitus (4 points), and prior stroke or TIA (6 points) to develop a scheme to predict the combination of ischemic plus hemorrhagic stroke (Table 1) . Whether the Framingham scheme will predict ischemic stroke in other AF populations is not clear.
For a variety of reasons, we evaluated only these 5 risk stratification schemes and excluded others. We excluded schemes that were based entirely on retrospective data. 19, 20 We excluded 2 schemes 21, 22 that were based on data used in the present analysis and another because the other study focused exclusively on secondary prevention. 7 We excluded the initial SPAF I scheme 6 because it was superseded by the subsequent SPAF and AFI schemes, both of which used SPAF I data. We excluded schemes that required the use of echocardiography to risk-stratify patients 23-27 because we did not have echocardiographic results on all participants and because we wished to validate a scheme that could predict stroke on the basis of clinical risk factors.
Description of the Validation Population
Participants with nonvalvular AF who took aspirin at dosages ranging between 75 and 325 mg daily in 6 prospective trials made up the validation cohort (Table 2 ). To validate the risk stratification schemes in an independent cohort of AF patients, patient data that were used to derive any of the 4 classification schemes were excluded from this analysis.
We used patient data from 6 prospective randomized trials. In 4 trials, participants were prescribed aspirin alone: the Atrial Fibrillation, Aspirin, Anticoagulation I (AFASAK-I; nϭ336) study, 28 the Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study (PATAF; nϭ319), 29 the European Atrial Fibrillation Trial (EAFT; nϭ404), 30 and the low-risk SPAF III study (nϭ891; 1 additional SPAF patient was excluded for missing information). 5 From the fifth trial, AFASAK-2, we included participants who were prescribed aspirin, either alone (nϭ169) or in combination with an ineffective, 1.25-mg dose of warfarin (nϭ171). 31 From the sixth trial, high-risk SPAF-III, 32 we included participants (nϭ290) who were prescribed aspirin in combination with low-dose warfarin (median dose 2 mg/d) if their international normalized ratio never exceeded 1.4 during follow-up. Adherence to aspirin therapy exceeded 85% in the studies in which it was reported. 5, 29, 33 Research coordinators and physicians recorded baseline patient characteristics at the time of enrollment in the original trials. We classified participants into the appropriate strata of each scheme using baseline clinical characteristics (Appendix). These characteristics included age, previous stroke or TIA, hypertension, cardiac disease, and diabetes. Patients were classified as hypertensive if they were taking medications given to lower blood pressure or if blood pressure exceeded 140/90 mm Hg. Because echocardiographic information was not available, we were unable to apply one of the stroke risk factors (decreased systolic function) of the ACCP and SPAF schemes. Likewise, because we could not ascertain the duration of congestive heart failure, we substituted any congestive heart failure for recent heart failure in the SPAF and CHADS 2 schemes. During follow-up in these trials, physicians assessed patients with suspected stroke. To identify etiology, a brain CT scan was done in 98% of incident neurological events. Strokes were defined as neurological deficits that persisted for more than 24 hours and that were not associated with an intracranial hemorrhage.
Statistical Analysis
Incidence rates for ischemic stroke were calculated as the number of strokes per 100 patient-years of observation. 34 For this calculation, observation started when participants were randomized to aspirin and ended when they experienced an ischemic stroke or were censored. Participants were censored for nonstroke death or study termination. To calculate 95% CIs, we used the Poisson distribution.
We used the weighted -statistic to compare the agreement between schemes corrected for chance agreement. 35 Because the -statistic requires the same number of risk strata for all schemes, we collapsed CHADS 2 scores into 3 strata (0, 1 to 2, and 3 to 6) and the Framingham scores into 3 strata (0 to 7, 8 to 13, and Ͼ13) for this comparison.
We quantified the discrimination of each stratification scheme using the log-rank test, the Wald 2 statistic from a Cox proportional hazards model, and the c-statistic. 36 Discrimination is the ability of the stratification schemes to separate the AF population into strata that have distinct stroke rates. 37 A c-statistic of 1.0 indicates perfect discrimination, which means that patients with different stroke risks are always correctly distinguished, whereas a value of 0.5 is noninformative. We bootstrapped 200 samples (with replacement) of the 2 and c-statistic values using a publicly available macro (http://ftp.sas.com/techsup/download/stat/) and compared the differences values between schemes by paired t tests. Statistical analyses were done with SAS software (SAS Institute Inc). All statistical tests were 2 sided, and probability values Ͻ0.05 were considered significant.
The Institutional Review Board of participating institutions approved the study.
Results
Characteristics of the Validation Cohort
The 2580 participants had a mean age of 72 years, 38% were female, and 22% had suffered a prior stroke or TIA ( Table 2 ). The most frequent risk factor was hypertension, which was present in 46%, and the least common was diabetes, with a 13% prevalence. Participants were followed up for a mean of 1.9 years (maximum 6.6 years). During 4887 patient-years of follow-up, there were 207 ischemic strokes, for an overall incidence rate of 4.2 strokes per 100 patient-years during aspirin therapy. The rate among the 2014 primary prevention participants without prior cerebral ischemia was 2.5 strokes per 100 patient-years of aspirin; for the 566 participants with a prior stroke or TIA, the rate was 10.8 per 100 patient-years of aspirin.
Stroke Rates According to Predicted Risk for Each Scheme
All schemes stratified the risk of ischemic stroke significantly better than chance (log-rank PϽ0.001 for all schemes), but the number of AF patients categorized as at high, moderate, and low risk varied substantially ( Table 3 ). The agreement between schemes was variable, with weighted -values ranging from a low of 0.13 (ACCP versus Framingham) to a high of 0.58 (ACCP versus AFI).
Comparison of the Classification Schemes
The stroke rates (95% CI) per 100 patient-years of aspirin rose with increasing CHADS 2 scores: 0.8 (0.4 to 1.7; nϭ469) with 0 points; 2.2 (1.6 to 3.1; nϭ752) with 1 point; 4.5 (3.5 to 5.9; nϭ670) with 2 points; 8.6 (6.8 to 11.0; nϭ428) with 3 points; 10.9 (7.8 to 15.2; nϭ200) with 4 points; 12.3 (6.6 to 22.9; nϭ56) with 5 points; and 13.7 (2 to 97; nϭ5) with 6 points. Rates (95% CI) per 100 patient-years of aspirin in other high-risk patients were lower than in the highest CHADS 2 cohorts: 6.1 (5.3 to 7.1) by AFI criterion, 6.5 (5.6 to 7.6) by SPAF, 5.1 (4.4 to 5.8) by ACCP, and 7.9 (6.5 to 9.7) for Framingham score Ͼ13.
Among primary prevention participants, CHADS 2 identified participants at high risk for stroke: primary prevention participants with 3 or 4 points averaged 5.3 (95% CI 3.3 to 8.4) strokes per 100 patient-years. In contrast, patients identified by other schemes as high risk had rates of 3.0 to 4.2 strokes per 100 patient-years (Table 3 ). The use of a higher Framingham threshold (Ͼ15 rather than Ͼ13 points; Table 3 ) identified 144 participants whose stroke rate was only 3.9.
A Cox proportional hazards model quantified the ability to discriminate between low-and high-risk patients by the likelihood ratio 2 Collapsing CHADS 2 into 3 strata (0, 1 to 2, and 3 to 6) yielded a 2 value of 86, and collapsing Framingham into 3 strata (0 to 7, 8 to 13, and Ͼ13) yielded a value of 69. When only primary prevention patients were analyzed, 2 values were lower, but the pattern was similar: AFI 18, SPAF 17, ACCP 17, CHADS 2 
Identification of Patients Whose Stroke Rate Was Low With Aspirin Therapy
ACCP criteria classified the fewest participants as low risk (nϭ182). In contrast, SPAF classified 668 participants as low risk (Table 3) . Primary prevention participants with a Framingham score of 4 or less (nϭ502) or 7 or less (nϭ983) both averaged 1.4 strokes per 100 patient-years. Primary prevention participants with 7 or fewer Framingham points who were not considered low risk by SPAF averaged 2.2 strokes per 100 patient-years; primary prevention participants with 7 or fewer Framingham points who had 1 or more CHADS 2 points averaged 1.9 strokes per 100 patient-years.
Discussion
This study of 2580 participants to whom aspirin had been prescribed confirms that AF populations with high and low stroke risks can be identified prospectively. Patients with a prior stroke or TIA averaged 10.8 strokes per 100 patientyears despite aspirin therapy. For these patients, it is clear that the benefits of anticoagulant therapy outweigh the risks. 30, 32, 38 Primary prevention patients whose stroke risk exceeds Ϸ4 per 100 patient-years of aspirin also benefit from warfarin therapy. 4, 10, 12 These patients were reliably identified by a CHADS 2 score Ն3. Such patients averaged 5.3 strokes per 100 patientyears of aspirin. The number needed to treat with warfarin instead of aspirin for 1 year to prevent 1 stroke would be Ϸ30 for these patients. 9, 12 High-risk primary prevention patients identified by the other schemes had stroke rates of only 3.0 to 4.2.
In contrast, all schemes successfully identified low-risk patients whose stroke rate was 1.4 or lower per 100 patient-years of aspirin, but the agreement between schemes was poor. Experts and patients typically prefer aspirin to warfarin when the risk is less than Ϸ2 strokes per 100 patient-years of aspirin. 9 -11 For these AF patients, the number needed to treat with warfarin for 1 year to prevent 1 stroke exceeds 100. The ability to characterize low-risk AF patients with confidence allows clinicians to identify patients who can safely be treated with aspirin, sparing them the risk of bleeding, cost, and inconvenience from anticoagulant therapy. 39, 40 Although the Framingham scheme identified the largest fraction of low-risk patients (almost half of the primary prevention cohort had a Framingham score of 7 or less), the additional low-risk patients identified had Ϸ2 strokes per 100 patient-years, a rate substantially greater than other low-risk cohorts.
For patients whose stroke risk is 2 to 4 per 100 patient-years of aspirin therapy, many experts offer warfarin, 41, 42 whereas others offer aspirin, 43, 44 depending on risk of hemorrhage and patient preferences. In clinical trials, warfarin increased the risk of major hemorrhage 1.7-fold compared with aspirin. 9 Outside of trials, the risk of hemorrhage was greater, 45, 46 depending on how warfarin was monitored 47 and risk factors for hemorrhage. 48 How patients trade off the risk of stroke, risk of hemorrhage, and the aggravation of taking and monitoring anticoagulant therapy depends on individual preferences. 10, 13, 14 The use of data from clinical trial cohorts confers both strengths and limitations to the present study. One strength is that similar sets of comorbid conditions were collected at baseline across different trials. A second strength is that ischemic strokes were identified prospectively by clinical examination and confirmed by computerized tomography. A third is that all patients received aspirin, which allowed us to quantify the stroke rate with this ubiquitous, inexpensive therapy. A fourth strength is that none of the patients included in these analyses were included as part of the derivation cohorts for any of the schemes. Finally, because the schemes were derived primarily from patients assigned to no antithrombotic therapy, the present study demonstrates that the schemes (especially CHADS 2 ) are valid predictors of stroke in patients prescribed aspirin.
One limitation is that participants with contraindications to warfarin therapy were included in only 1 of the 6 trials. The inclusion of more of these patients would have provided greater generalizability, but such patients were excluded from clinical trials. Second, echocardiographic results were not available, which would have allowed us to assess whether they would have improved the predictive accuracy of the schemes that consider left ventricular systolic dysfunction as a stroke risk factor. Thus, the SPAF criteria for impaired left ventricular function could not be tested, and a history of heart failure was used instead. A finding of significant systolic dysfunction by echocardiography primarily would be relevant to patients at low risk of stroke on the basis of clinical factors. 24, 49 Recent retrospective studies of other AF populations further validate CHADS 2 . For example, enrollees of Kaiser Permanente (Northern California) who were not prescribed warfarin (4% of whom had a prior stroke) had a very low stroke rate (0.5 per 100 patient-years) if their CHADS 2 score was 0. Their stroke rates were greater with greater CHADS 2 scores: 1.5 for 1 point, 2.5 for 2 points, 5.3 for 3 points, 6.0 for 4 points, and 6.9 for 5 or 6 points. 46 Although other schemes were not evaluated by these studies, it confirms the ability of CHADS 2 to identify low-and high-risk patients reliably.
In the future, a more accurate prediction rule for stroke may be possible by incorporating additional factors. For example, left ventricular systolic dysfunction detected by 2D transthoracic echocardiography is an independent risk factor for stroke in AF. 24 Also, it seems likely that hormone replacement therapy 21, 50 and cigarette smoking 51 increase the risk of stroke in AF, whereas modest alcohol consumption may decrease it. 21 Finally, future studies will determine whether biochemical markers of inflammation (eg, C-reactive protein) or endothelial dysfunction (eg, von Willebrand factor) will help clinicians predict stroke in the AF population. 
